Financials data is unavailable for this security.
View more
Year on year Travere Therapeutics Inc grew revenues 32.69% from 109.46m to 145.24m while net income improved from a loss of 278.48m to a smaller loss of 111.40m.
Gross margin | 94.70% |
---|---|
Net profit margin | -215.85% |
Operating margin | -221.66% |
Return on assets | -59.56% |
---|---|
Return on equity | -582.60% |
Return on investment | -74.41% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Travere Therapeutics Inc fell by 3.51m. Cash Flow from Financing totalled 218.75m or 150.62% of revenues. In addition the company used 280.02m for operations while cash from investing totalled 55.78m.
Cash flow per share | -4.53 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1981 |
---|---|
Tangible book value per share | -1.18 |
More ▼
Balance sheet in USDView more
Current ratio | 3.04 |
---|---|
Quick ratio | 2.99 |
Total debt/total equity | 24.96 |
---|---|
Total debt/total capital | 0.9615 |
More ▼